TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33600134

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2 mg, three monthly doses
Number of subjects: 50
Study: 32826003

Group type: EXPERIMENTAL
Intervention: Active WBV (35 Hz)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham WBV
Number of subjects: 28
Study: 35177515

Group type: EXPERIMENTAL
Intervention: Previsit patient activation card
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 34214704

Group type: EXPERIMENTAL
Intervention: Eosinophilic esophagitis (EoE)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Non-eosinophilic gastrointestinal disorders (non-EoE EGIDs)
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: Non-EoE EGIDs in children
Number of subjects: 786
Study: 36368325

Group type: EXPERIMENTAL
Intervention: relatively easy criteria for success (RES)
Number of subjects: 48

Group type: COMPARATOR
Intervention: control
Number of subjects: 48
Study: 33751849

Group type: EXPERIMENTAL
Intervention: Anagliptin
Number of subjects: 765
Study: 32527353

Group type: EXPERIMENTAL
Intervention: Xuebijing
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 33476425

Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS with 2000 pulses
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 5-Hz with 500 pulses per session
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 10-Hz with 500 pulses per session
Number of subjects: 22

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 22
Study: 34223734

Group type: EXPERIMENTAL
Intervention: 20 mg/kg Genistein (GEN)
Number of subjects: 80
Study: 32120880

Group type: EXPERIMENTAL
Intervention: Physical activity break (10 min of moderate intensity activities such as star jumps)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control condition (10 min of playing a vocabulary game)
Number of subjects: 68
Study: 35467040

Group type: EXPERIMENTAL
Intervention: Zirconia veneered with feldspar ceramics
Number of subjects: 20

Group type: COMPARATOR
Intervention: Titanium
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zirconia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PEEK
Number of subjects: 20
Study: 33368319

Group type: EXPERIMENTAL
Intervention: 7-day stored RBCs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 42-day stored RBCs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 28-day stored RBCs
Number of subjects: 30
Study: 32664066

Group type: EXPERIMENTAL
Intervention: Nurse or pharmacist-led aggressive control of comorbidities
Number of subjects: 400

Group type: COMPARATOR
Intervention: Currently practiced best risk factor management strategies
Number of subjects: 400
Study: 35426763

Group type: EXPERIMENTAL
Intervention: Experienced basketball players
Number of subjects: 48

Group type: COMPARATOR
Intervention: Novice basketball players
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 32749733

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Standard therapy only (Control)
Number of subjects: 1000
Study: 36308446

Group type: EXPERIMENTAL
Intervention: Anticoagulated group (warfarin + aspirin)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (aspirin only)
Number of subjects: 140
Study: 34597899

Group type: EXPERIMENTAL
Intervention: Sepranolone 10 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Sepranolone 16 mg
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 32464527

Group type: EXPERIMENTAL
Intervention: CLIP intervention (community engagement, community health worker-provided mobile health-guided clinical assessment, initial treatment, and referral)
Number of subjects: 15013

Group type: EXPERIMENTAL
Intervention: CLIP intervention with ≥8 contacts
Number of subjects: 15013

Group type: COMPARATOR
Intervention: Control group (no CLIP contacts)
Number of subjects: 15013
Study: 35468266

Group type: EXPERIMENTAL
Intervention: Group-based outpatient physical therapy delivered 6 weeks after TKR, costing £179 ± 39 per patient.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 180
Study: 35189843

Group type: EXPERIMENTAL
Intervention: Tablet-based video intervention about IPV and safety behaviours
Number of subjects: 317

Group type: COMPARATOR
Intervention: Control video promoting healthy pregnancy
Number of subjects: 317
Study: 34049809

Group type: EXPERIMENTAL
Intervention: 0.1% HA eye drops during hydrogel SCL wear
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.2% HA eye drops during hydrogel SCL wear
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.3% HA eye drops during silicone-hydrogel SCL wear
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 33040096

Group type: EXPERIMENTAL
Intervention: Restriction of mobile phone use over time
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cognitive and sensory distractions
Number of subjects: 64
Study: 35456220

Group type: EXPERIMENTAL
Intervention: Intragastric botulinum toxin A (BT‐A) injection
Number of subjects: 46

Group type: COMPARATOR
Intervention: Physiological saline solution (control)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intragastric botulinum toxin A (BT‐A) injection (BMI > 50 kg/m2)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Physiological saline solution (control) (BMI > 50 kg/m2)
Number of subjects: 46
Study: 32286882

Group type: EXPERIMENTAL
Intervention: 16 weeks of supervised, moderate-intensity aerobic exercise
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional lifestyle advice
Number of subjects: 27
Study: 34583219

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting cancer-specific survival (CSS)
Number of subjects: 4238

Group type: EXPERIMENTAL
Intervention: Risk classification system
Number of subjects: 4238

Group type: EXPERIMENTAL
Intervention: Calibration curves
Number of subjects: 4238

Group type: EXPERIMENTAL
Intervention: Decision Curve Analyses (DCAs)
Number of subjects: 4238

Group type: EXPERIMENTAL
Intervention: Cox regression analyses
Number of subjects: 4238
Study: 36246130

Group type: EXPERIMENTAL
Intervention: Continuous aerobic exercise group (AerG)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Interval aerobic exercise group (IntG)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combined exercise group (ComG)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 102
Study: 33354715

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 109

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 109
Study: 35667527

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) planned for 332 lesions in 296 separate PTVs, with common prescriptions of 30-35 Gy in 5 fractions (43% of lesions) and 20-24 Gy in 1 fraction (33% of lesions).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) for spinal targets.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR) for lymph node targets.
Number of subjects: 60
Study: 32655007

Group type: EXPERIMENTAL
Intervention: 81 mg/day aspirin
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: 325 mg/day aspirin
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 36351419

Group type: EXPERIMENTAL
Intervention: Static posturography‐assisted biofeedback exercises (n=20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional exercise program (n=21)
Number of subjects: 41
Study: 33528816

Group type: EXPERIMENTAL
Intervention: Multi-period design with varying weekly measurement schemes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Planned missing data designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dropout modeled by the Weibull survival function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Few subjects per day and a large number of weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waiting room environments in dental care
Number of subjects: 0
Study: 36379663

Group type: EXPERIMENTAL
Intervention: Symptoms clinic intervention plus usual care
Number of subjects: 354

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 354
Study: 33629536

Group type: EXPERIMENTAL
Intervention: Mastiha
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 32343882

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Adalimumab 40 mg
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg plus MTX
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg plus MTX
Number of subjects: 1148

Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 1148
Study: 34143354

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) training for primary care providers
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no MI training)
Number of subjects: 36
Study: 34836131

Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Higher prostaglandin E2 (PGE2) levels
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Higher 5-hydroxyeicosatetraenoic acid (5-HETE) levels
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Higher PGE2 levels
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Oxylipins
Number of subjects: 256
Study: 34905388

Group type: EXPERIMENTAL
Intervention: HAIC-FO
Number of subjects: 262

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: HAIC-FO responders
Number of subjects: 262
Study: 36205271

Group type: EXPERIMENTAL
Intervention: Peer-Assisted Learning (PAL)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Traditional Faculty-led Teaching (non-PAL)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Comparison of PAL and non-PAL
Number of subjects: 77
Study: 33908117

Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum (0.2 mL of human milk)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo (0.2 mL of placebo)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of colostrum
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 32045077

Group type: EXPERIMENTAL
Intervention: Clinical psychologist‐facilitated group intervention (9 groups over 3 weeks)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 238
Study: 35908296

Group type: EXPERIMENTAL
Intervention: immediate-use App (iApp group; n = 47)
Number of subjects: 95

Group type: COMPARATOR
Intervention: delayed-use App (dApp group; n = 48)
Number of subjects: 95
Study: 33691699

Group type: EXPERIMENTAL
Intervention: Stepwise CMD risk assessment and individualized treatment
Number of subjects: 1934

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 1934
Study: 32125052

Group type: EXPERIMENTAL
Intervention: Virtual Conversational Agent (VCA) interface
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard interface
Number of subjects: 50
Study: 36163721

Group type: EXPERIMENTAL
Intervention: Auto-HSCT
Number of subjects: 111

Group type: COMPARATOR
Intervention: ChT
Number of subjects: 111
Study: 34273987

Group type: EXPERIMENTAL
Intervention: Intravenous LPS (Escherichia coli O113, 2 ng/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 36469573

Group type: COMPARATOR
Intervention: Neoadjuvant durvalumab (monotherapy)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neoadjuvant durvalumab plus tremelimumab (combination therapy)
Number of subjects: 20
Study: 34118298

Group type: EXPERIMENTAL
Intervention: Delgocitinib 0.25% ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle ointment (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delgocitinib 0.25% or 0.5% ointment (Part 2)
Number of subjects: 0
Study: 32947424

Group type: EXPERIMENTAL
Intervention: Pregnenolone adjunct to risperidone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo adjunct to risperidone
Number of subjects: 64
Study: 35477444

Group type: EXPERIMENTAL
Intervention: Ultrasound visual biofeedback (U‐VBF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard articulatory intervention
Number of subjects: 40
Study: 33004234

Group type: EXPERIMENTAL
Intervention: CAMP Air (n = 30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Information-and-referral control intervention (n = 31)
Number of subjects: 61
Study: 36349299

Group type: EXPERIMENTAL
Intervention: Nomogram based on the triglyceride-glucose index
Number of subjects: 1073
Study: 35714121

Group type: EXPERIMENTAL
Intervention: Multi-component rehabilitation intervention including access to an information book about cardiac disease, patient supporters, information materials for employers, rehabilitation goal setting plan, support café for relatives, follow-up phone calls from physiotherapists, and additional support for vulnerable patients.
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Multi-component rehabilitation intervention as described above.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Usual care at the hospital including rehabilitation-needs-assessment, patient education, and physical training.
Number of subjects: 182
Study: 32316014

Group type: EXPERIMENTAL
Intervention: TCD-guided BP control (TBC)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Non-TCD-guided BP control (NBC)
Number of subjects: 95
Study: 35346889

Group type: EXPERIMENTAL
Intervention: Maternal glycemic control (fasting and 1-hour postprandial or serial intrapartum capillary blood glucose screening with insulin treatment as indicated)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Expectant management (no glucose screening or treatment)
Number of subjects: 86
Study: 33635171

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS) for 12 weeks followed by monthly maintenance treatment
Number of subjects: 116
Study: 33965514

Group type: EXPERIMENTAL
Intervention: NTCP model based on mandible bone D30% and pre-RT dental extraction
Number of subjects: 1259
Study: 34083504

Group type: EXPERIMENTAL
Intervention: High-dose melphalan (HDM)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 321

Group type: COMPARATOR
Intervention: MRD-negative patients
Number of subjects: 321
Study: 33730349

Group type: EXPERIMENTAL
Intervention: Estimated glucose disposal rate (eGDR)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Higher-risk group (56% of patients)
Number of subjects: 32
Study: 32384922

Group type: EXPERIMENTAL
Intervention: Logbook
Number of subjects: 235

Group type: COMPARATOR
Intervention: No logbook
Number of subjects: 235
Study: 33741732

Group type: EXPERIMENTAL
Intervention: Camrelizumab (3 mg/kg, once every 2 weeks) plus apatinib (375 mg, once per day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Camrelizumab (3 mg/kg, once every 2 weeks) plus apatinib (500 mg, once per day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Camrelizumab (3 mg/kg, once every 2 weeks) plus apatinib (250 mg, once per day)
Number of subjects: 28
Study: 33359589

Group type: EXPERIMENTAL
Intervention: Daily dosing of PTAH (cohorts 1 and 3A)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Non-daily dosing of PTAH (cohorts 2, 3B, and 3C)
Number of subjects: 358

Group type: COMPARATOR
Intervention: PTAH-naive participants receiving 300 mg/d PTAH
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: PTAH-continuing participants
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: PTAH treatment beyond 1 year
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Changes in immune markers with PTAH continuation
Number of subjects: 358
Study: 32194196

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 4731

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4731
Study: 35364479

Group type: EXPERIMENTAL
Intervention: Dual-task intervention (DTI)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Iranian dance intervention (IDI)
Number of subjects: 38
Study: 35596975

Group type: EXPERIMENTAL
Intervention: AI-based chatbot conversations
Number of subjects: 20
Study: 37072702

Group type: EXPERIMENTAL
Intervention: Video-assisted laryngoscopy with Macintosh-shaped blade
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Video-assisted laryngoscopy with hyperangulated blade
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Direct laryngoscopy with Macintosh blade (standard of care)
Number of subjects: 2500
Study: 33495008

Group type: EXPERIMENTAL
Intervention: GH 4 IU/day subcutaneous injection
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (subcutaneous saline)
Number of subjects: 156
Study: 35093490

Group type: EXPERIMENTAL
Intervention: DI+TAU
Number of subjects: 83

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 83
Study: 34602396

Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with dexmedetomidine and propofol combined with seaweed polysaccharides
Number of subjects: 82

Group type: COMPARATOR
Intervention: Intravenous anesthesia with sufentanil combined with propofol
Number of subjects: 82
Study: 34882571

Group type: EXPERIMENTAL
Intervention: Interactive Decision Support Tool (DST)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Static Decision Support Tool (DST)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (no DST)
Number of subjects: 196
Study: 32746948

Group type: EXPERIMENTAL
Intervention: High-sugar food/beverage advertisements
Number of subjects: 101

Group type: COMPARATOR
Intervention: Toy advertisements
Number of subjects: 101
Study: 32251844

Group type: EXPERIMENTAL
Intervention: Colistin plus meropenem (synergism group)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Colistin plus meropenem (additivism/indifference group)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Colistin plus meropenem (antagonism group)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Colistin monotherapy (control group)
Number of subjects: 171
Study: 32341244

Group type: EXPERIMENTAL
Intervention: Deadlifts performed with lifting straps (DLw)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Deadlifts performed without lifting straps (DLn)
Number of subjects: 16
Study: 34958402

Group type: EXPERIMENTAL
Intervention: Medication therapy for osteoporosis
Number of subjects: 3670

Group type: EXPERIMENTAL
Intervention: Subjects with periodontal disease
Number of subjects: 3670

Group type: COMPARATOR
Intervention: Subjects without periodontal disease
Number of subjects: 3670
Study: 34259871

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Quit attempts
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Motivation to quit
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Readiness to quit smoking
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Use of smoking cessation medication
Number of subjects: 300
Study: 33855995

Group type: EXPERIMENTAL
Intervention: Legacy intervention (electronic digital storyboards)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 32967393

Group type: EXPERIMENTAL
Intervention: Ashi acupuncture
Number of subjects: 35

Group type: COMPARATOR
Intervention: Local anesthetic injections
Number of subjects: 35
Study: 32991509

Group type: EXPERIMENTAL
Intervention: Composite training (COMP group, n = 10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sprint training (SPRINT group, n = 11)
Number of subjects: 21
Study: 34790041

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no HBOT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Blank group (no HBOT)
Number of subjects: 90
Study: 32819988

Group type: EXPERIMENTAL
Intervention: Culturally adapted mass media campaign (TV, radio, print media and social media)
Number of subjects: 676
Study: 33146706

Group type: EXPERIMENTAL
Intervention: Antepartum TPT initiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postpartum TPT initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antepartum TPT initiation with nevirapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postpartum TPT initiation with nevirapine
Number of subjects: 0
Study: 35974933

Group type: EXPERIMENTAL
Intervention: ISR with MACE
Number of subjects: 30

Group type: COMPARATOR
Intervention: ISR without MACE
Number of subjects: 30
Study: 34340163

Group type: EXPERIMENTAL
Intervention: Early physical therapy (PT) treatment including exercise instructions from the first postoperative day
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Early physical therapy (PT) treatment
Number of subjects: 157
Study: 35976959

Group type: EXPERIMENTAL
Intervention: 8-week interval (males)
Number of subjects: 44863

Group type: EXPERIMENTAL
Intervention: 10-week interval (males)
Number of subjects: 44863

Group type: COMPARATOR
Intervention: 12-week interval (males)
Number of subjects: 44863

Group type: EXPERIMENTAL
Intervention: 12-week interval (females)
Number of subjects: 44863

Group type: EXPERIMENTAL
Intervention: 14-week interval (females)
Number of subjects: 44863

Group type: COMPARATOR
Intervention: 16-week interval (females)
Number of subjects: 44863

Group type: COMPARATOR
Intervention: 8-week vs 12-week interval (males)
Number of subjects: 44863

Group type: COMPARATOR
Intervention: 12-week vs 16-week interval (females)
Number of subjects: 44863
Study: 33904585

Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 47
Study: 32228235

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine augmentation
Number of subjects: 0
Study: 36125177

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan initiated pre-discharge
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan initiated post-discharge
Number of subjects: 991